Diabetes Technology & Therapeutics · 2021 · 15 citations · 8 references
MedicineHealth Services AdministrationInternal MedicineDiabetologyGeneral Internal MedicinePopulation Health ManagementChronic Disease DisparitiesDiabetes ControlDiabetes ManagementDiabetes MellitusEthnicity In HealthGlycemic ControlBarriersClosed-loop Insulin DeliveryDiabetes Care Quality ImprovementDiabetes Mellitus ManagementImplementation In Underserved PopulationsInfusion Pump UseInsulin Delivery DevicesInsulin Pumps
We retrospectively evaluated outcomes of the Minimed Medtronic 670G system in an academic urban safety-net population of adults with type 1 diabetes, between September 2016 and January 2020. Among 32 patients prescribed the 670G, the majority were female (69%), white (69%), achieved advanced degrees (56%), were commercially insured (94%), and were experienced pump users (84%). Patients who initiated auto-mode demonstrated significant improvement in A1c after 1 year. However, 31% of patients never initiated auto-mode. Black and Hispanic patients comprised 50% of this group, despite similar insurance coverage, diabetes duration, educational level, and prior pump use. Hence, traditional barriers to technology use do not explain these racial/ethnic disparities. Of 22 patients who initiated auto-mode, 5 discontinued within 1 year. The most common reason for discontinuation was frustration with pump-sensor interactions. Future studies identifying barriers to and strategies for increasing use of advanced insulin delivery systems in underserved populations are needed.
8
One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System
Rayhan Lal, Marina Basina, David M. Maahs et al. · Diabetes Care · 2019 · 212 citations · Full text
Medicine, Endocrinology, Pediatrics +17